荣昌生物制药（烟台）股份有限公司_荣昌生物

Lang

Information Disclosure

}

04 2025.07

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
26 2025.06

POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING, THE 2025 FIRST CLASS MEETING OF A SHAREHOLDERS AND THE 2025 FIRST CLASS MEETING OF H SHAREHOLDERS
26 2025.06

INSIDE INFORMATION
04 2025.06

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
29 2025.05

Next Day Disclosure Return
29 2025.05

COMPLETION OF PLACING OF H SHARES
27 2025.05

VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR TELITACICEPT FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN CHINA
26 2025.05

TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF THE COMPANY
26 2025.05

TERMS OF REFERENCE OF THE NOMINATION COMMITTEE UNDER THE BOARD OF THE COMPANY
26 2025.05

TERMS OF REFERENCE OF THE AUDIT COMMITTEE UNDER THE BOARD OF THE COMPANY

1/62

Jump To

1/5

Jump To

1/1

Jump To

Corporate Governance

1/1

Jump To

IR Contacts

Telephone：0535-3573685

Email：IR@REMEGEN.COM